Squarepoint Ops LLC Passage Bio, Inc. Transaction History

Squarepoint Ops LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.82 - $1.19 $57,163 - $82,957	69,712 New	69,712 $65,000
Q4 2022 Feb 14, 2023	BUY	$1.06 - $1.48 $757 - $1,058	715 Added 6.49%	11,728 $16,000
Q3 2022 Nov 14, 2022	BUY	$1.22 - $2.48 $13,435 - $27,312	11,013 New	11,013 $14,000
Q2 2022 Aug 15, 2022	SELL	$1.63 - $3.46 $75,804 - $160,910	-46,506 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$2.66 - $6.49 $30,185 - $73,648	-11,348 Reduced 19.61%	46,506 $144,000
Q4 2021 Feb 14, 2022	BUY	$6.24 - $10.2 $213,988 - $349,788	34,293 Added 145.55%	57,854 $367,000
Q3 2021 Nov 15, 2021	SELL	$9.73 - $15.52 $64,519 - $102,913	-6,631 Reduced 21.96%	23,561 $235,000
Q2 2021 Aug 16, 2021	SELL	$12.44 - $19.45 $281,268 - $439,764	-22,610 Reduced 42.82%	30,192 $400,000
Q1 2021 May 17, 2021	BUY	$16.24 - $29.83 $727,454 - $1.34 Million	44,794 Added 559.37%	52,802 $923,000
Q4 2020 Feb 16, 2021	SELL	$14.28 - $29.73 $41,083 - $85,533	-2,877 Reduced 26.43%	8,008 $205,000
Q3 2020 Nov 16, 2020	BUY	$12.39 - $26.15 $134,865 - $284,642	10,885 New	10,885 $143,000

32.7M

8.3K

400

Ticker PASG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,463,200
Market Cap $38.1M
Description
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

Stay updated on Squarepoint Ops LLC with notifications on news.